探讨吉西他滨联合奥沙利铂治疗耐药性晚期乳腺癌的临床价值

目的 探讨吉西他滨联合奥沙利铂治疗耐药性晚期乳腺癌的临床应用价值.方法 随机选取2012年6月—2015年6月期间该院收治的耐药性晚期乳腺癌患者50例,所有患者均以吉西他滨联合奥沙利铂进行治疗.对患者的临床治疗效果进行分析. 结果 在2疗程治疗后,完全缓解患者6例;部分缓解患者19例;稳定患者22例;进展患者3例.结论 吉西他滨联合奥沙利铂治疗耐药性晚期乳腺癌效果较为理想,可有效延长患者的生存时间,改善患者预后.

Clinical Value of Gemcitabine Combined with Oxaliplatin in the Treatment of Resistant Advanced Breast Cancer

Objective To discuss the clinical application value of gemcitabine combined with oxaliplatin in the treatment of resistant advanced breast cancer. Methods 50 cases of patients with resistant advanced breast cancer treated in our hospital from June 2012 to June 2015 were selected and all of the patients were given gemcitabine combined with oxaliplatin treat-ment, the clinical treatment effects of the patients were analyzed. Results After 2 courses of treatment, 6 cases were com-plete remission, 19 cases were partial remission, 22 cases were stable patients and 3 cases were progress patients. Conclu-sion Gemcitabine combined with oxaliplatin in the treatment of resistant advanced breast cancer has an ideal effect, which can effectively prolong the survival time and improve prognosis of patients.